Sanofi, Novartis and Novo Nordisk Lead Week of Multi-Billion-Dollar Healthcare Deals

โดย Seeking Alpha·USCNDK·Read original
Summary · why it matters

A Delaware federal judge on Monday rejected requests from Pfizer, BioNTech and Moderna to dismiss lawsuits filed by Bayer's Monsanto unit over their use of US Patent No. 7,741,118, a patent related to mRNA technology, with Judge William Bryson saying the companies failed to prove the patent was invalid or not infringed by their COVID-19 vaccines. Sanofi agreed to a deal worth up to $8B, including $1B upfront, with Regeneron to jointly develop four long-acting immunology therapies, led by the clinical-stage IL-13 monoclonal antibody REGN20423. China's Abogen Biosciences signed a licensing and option agreement with Novartis worth up to $7.8B, comprising a $575 million upfront payment and up to approximately $7.2 billion in potential milestone payments if all options on all programs are exercised, covering an exclusive worldwide license to Abogen's lead asset ABO2203. Jiangsu Hengrui Pharmaceuticals agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk in a deal worth up to $2.6B, with $300M upfront and the transaction expected to close in Q4 2026. Meanwhile, the S&P 500 Health Care Sector Index slipped 2.66% for the week, with Incyte down 6.93% and Regeneron down 6.71% among the top decliners, while McKesson rose 4.11% and Cardinal Health gained 3.67%.

Impact on assets 19

Biotech & Genomic Medicine± Mixed · 10 stocks
Novartis AG
NOVN
▲ PositiveDemandrelevance

Novartis signed a licensing and option agreement with Abogen worth up to $7.8B covering ABO2203.

BioNTech SE
22UA
▼ NegativeRegulationrelevance

Delaware judge rejected BioNTech's motion to dismiss Monsanto's mRNA patent lawsuits over its COVID-19 vaccine.

Moderna Inc
MRNA
▼ NegativeRegulationrelevance

Delaware judge rejected Moderna's motion to dismiss Monsanto's mRNA patent infringement lawsuits over its COVID-19 vaccine.

Pfizer Inc
PFE
▼ NegativeRegulationrelevance

Judge rejected Pfizer's request to dismiss Monsanto's mRNA patent infringement lawsuits over its COVID-19 vaccine.

Regeneron Pharmaceuticals Inc
REGN
▲ PositiveDemandrelevance

Regeneron agreed to an up-to-$8B deal with Sanofi to jointly develop four long-acting immunology therapies led by REGN20423.

Health Care▲ · 5 stocks
Sanofi SA
SAN
▲ PositiveDemandrelevance

Sanofi agreed to an up-to-$8B deal with Regeneron to jointly develop four long-acting immunology therapies.

Bayer AG NA
BAYN
▲ PositiveRegulationrelevance

Bayer's Monsanto unit won the ruling allowing its mRNA patent infringement lawsuits against Pfizer, BioNTech and Moderna to proceed.

Longevity & Life Extension▲ · 1 stocks
Novo Nordisk A/S
NVO
▲ PositiveDemandrelevance

Novo Nordisk licensed global rights to Hengrui's experimental obesity drug HRS-1596 in a deal worth up to $2.6B, expanding its pipeline.

Robotics & Physical AI▲ · 1 stocks
Aging Population▲ · 1 stocks
Others▲ · 1 stocks

Theme Impact 4

Off-coverage companies 1

Abogen BiosciencesPrivate▲ Positive
Demandrelevance

Abogen Biosciences licensed its lead asset ABO2203 to Novartis in a deal worth up to $7.8B.

Related news

United StatesCanadaUnited Kingdom
▼

HSBC Upgrades Target, Citi Downgrades Moderna in Week of Analyst Calls

Wall Street analysts issued a slew of rating changes this week, led by HSBC's upgrade of Target to Buy from Hold with a price target raised to $190 from $125, citing a turnaround "gaining momentum." Citi downgraded Moderna to Sell from Neutral, calling the valuation "unjustifiable" after the biotech rallied more than 222% since a Phase 3 win for its personalized cancer shot intismeran autogene, and cut its price target to $60 from $80. Deutsche Bank downgraded PepsiCo to Hold from Buy, while Goldman Sachs upgraded Occidental Petroleum to Buy from Neutral with a $69 price target, up from $63, and double-downgraded Tourmaline Oil to Sell from Buy with a C$49 target, cut from C$59. Wells Fargo upgraded Consolidated Edison to Overweight from Equal Weight with a $118 target and BP to Overweight from Equal Weight with a $57 target, while downgrading ExxonMobil to Equal Weight from Overweight with an unchanged $182 target. Morgan Stanley reinstated Nvidia as its top pick in the semiconductor space.
BP.LSEEDHSBA.LSEMRKMRNANVDA+4
Biotech & Genomic Medicine ▼
About megatrends
Biotech & Genomic Medicine › mRNA Platforms ▼Capital
Read original ↗
Seeking Alpha·1dRead more →
United States

Wells Fargo Starts Design Therapeutics at Overweight on Friedreich Ataxia Program

Wells Fargo initiated coverage of Design Therapeutics with an overweight rating, citing the company's Friedreich ataxia candidate DT-216P2 as having potentially best-in-disease functional improvement based on results from the RESTORE-FA study released in May. The bank set a $26 price target, implying roughly 112% upside based on the October 1 close. Analyst TianQi Hang wrote that the May update showed pharmacokinetics look good, and that blood-FXN protein, muscle-mRNA data, plus an early mFARS signal further de-risk the platform. Hang estimates that the blood FXN protein increase seen after 6 weeks can translate to at least a 2-point mFARS change, and said that if the drug kinetics sustain for 12 weeks, which he believes they will, DT-216P2 could deliver best-in-disease functional benefits. He assigns DT-216P2 a 60% probability of success, with peak sales of approximately $600M in the US and approximately $900M outside it. If approved, DT-216P2 would compete against Biogen's Skyclarys, also known as omaveloxolone, and Hang sees it gaining a peak share of the FA treatment market of 30% in the US and 20% ex-US.
BIIBDSGNWFC
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › Rare Disease ▲Competition
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Competition
Biotech & Genomic Medicine › RNAi / Antisense Oligonucleotides Competition
Biotech & Genomic Medicine › RNA Therapeutics ▲Competition
Read original ↗
Seeking Alpha·2dRead more →
United States
▲

Nasdaq 100 to Add Moderna, Replacing Warner Bros. Discovery, Effective Oct. 9

Nasdaq announced yesterday that shares of Moderna, the vaccine maker, will replace Warner Bros. Discovery in the Nasdaq 100 index, effective Oct. 9. The change follows a more than sixfold surge in Moderna's share price this year, giving the company a market value of about 75 billion dollars. Conversely, Warner Bros. Discovery will also be removed from the indexes of major index providers MSCI and S&P, as its merger with Paramount Skydance is expected to be completed on Oct. 6, after the process was delayed for many months.
MRNA ▲WBD ▼PSKY
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › mRNA Platforms ▲Capital
Biotech & Genomic Medicine › RNA Therapeutics ▲Capital
MRNA · Capital · Positive Moderna will be added to the Nasdaq 100 index, effective Oct. 9, following a sixfold share-price surge.
WBD · Capital · Negative Warner Bros. Discovery will be removed from the Nasdaq 100, MSCI, and S&P indexes as its merger with Paramount Skydance nears completion.
PSKY · Capital · Neutral Paramount Skydance's merger with Warner Bros. Discovery is expected to complete Oct. 6, but the article does not state the impact on Paramount.
Read original ↗
InfoQuest·2dRead more →
© 2026 MarketDXNews